Clinical Trial Update: Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 1/2 study of docetaxel, irinotecan, and carboplatin in extensive-stage unresectable non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Kentuckiana Cancer Institute | Conditions: Non-small Cell Lung Cancer, Extensive Stage Unresectable | Phase 1, Phase 2 | Status: TERMINATED